Detalhe da pesquisa
1.
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.
Cancer Immunol Immunother
; 70(10): 2991-3000, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33745032
2.
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates.
Clin Cancer Res
; 29(5): 878-887, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36534523
3.
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents.
J Hematol Oncol
; 15(1): 103, 2022 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35922861
4.
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Clin Cancer Res
; 27(17): 4710-4716, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34131002